Table IV.
Comparison of the predictive powers for gastric cancer between RNF180, DAPK1 and SFRP2 methylation alone and in combination.
| Gene methylation | Sensitivity, % (95% CI) | Specificity, % (95% CI) | Odds ratio (95% CI) | P-value |
|---|---|---|---|---|
| RNF180 | 57.89 (44.08–70.86) | 76.19 (60.55–87.95) | 4.40 (1.82–10.65) | 0.0007 |
| DAPK1 | 49.12 (35.63–62.71) | 71.43 (55.42–84.28) | 2.41 (1.03–5.633) | 0.0394 |
| SFRP2 | 71.93 (58.46–83.03) | 57.14 (40.96–72.28) | 3.42 (1.47–7.92) | 0.0036 |
| RNF180 + DAPK1 | 76.79 (63.58–87.02) | 59.52 (43.28–74.37) | 4.86 (2.03–11.66) | 0.0003 |
| RNF180 + SFRP2 | 85.96 (74.21–93.74) | 47.62 (32.00–63.58) | 5.57 (2.13–14.57) | 0.0002 |
| DAPK1 + SFRP2 | 82.46 (70.09–91.25) | 42.86 (27.72–59.04) | 3.53 (1.41–8.81) | 0.0057 |
| RNF180 + DAPK1 + SFRP2 | 87.72 (76.32–94.92) | 38.10 (23.57–54.36) | 4.40 (1.61–12.03) | 0.0026 |
RNF180, ring finger protein 180; DAPK1, death-associated protein kinase 1; SFRP2, secreted frizzled-related protein 2; CI, confidence interval.